KR101530721B1 - Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는 화합물 및 방법 - Google Patents
Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는 화합물 및 방법 Download PDFInfo
- Publication number
- KR101530721B1 KR101530721B1 KR1020097012239A KR20097012239A KR101530721B1 KR 101530721 B1 KR101530721 B1 KR 101530721B1 KR 1020097012239 A KR1020097012239 A KR 1020097012239A KR 20097012239 A KR20097012239 A KR 20097012239A KR 101530721 B1 KR101530721 B1 KR 101530721B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- bcl
- pharmaceutical composition
- compound
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CN(C)CCC(CC(C1CCCCC1)c1c(*)cccc1)*Cc1cc(CNO)ccc1 Chemical compound CN(C)CCC(CC(C1CCCCC1)c1c(*)cccc1)*Cc1cc(CNO)ccc1 0.000 description 8
- BIDYRJHZIAJQJS-WVQGLOJKSA-N CC(C)C[C@@H](CN(C)C)N(Cc1ccc[n]1C)Cc1cc(CN([C@@H]([C@@H]2[C@H](C)O)C(N[C@@H]3[C@@H](C)[C@H](C4)C(C)(C)[C@H]4C3)=O)NCC/C2=C\O)ccc1 Chemical compound CC(C)C[C@@H](CN(C)C)N(Cc1ccc[n]1C)Cc1cc(CN([C@@H]([C@@H]2[C@H](C)O)C(N[C@@H]3[C@@H](C)[C@H](C4)C(C)(C)[C@H]4C3)=O)NCC/C2=C\O)ccc1 BIDYRJHZIAJQJS-WVQGLOJKSA-N 0.000 description 1
- LAQRAWAMCKIRRY-BJMKKKEASA-N CCCOc1c(CN(Cc2cccc(CN3O[C@@H](CO)[C@@H]([C@H](C)O)[C@H]3C(N[C@]3([C@H]4C)C5[C@@H]4C(C)(C)[C@H]5C3)=O)c2)[C@@H](CC(C)C)CN2CCCC2)cccc1 Chemical compound CCCOc1c(CN(Cc2cccc(CN3O[C@@H](CO)[C@@H]([C@H](C)O)[C@H]3C(N[C@]3([C@H]4C)C5[C@@H]4C(C)(C)[C@H]5C3)=O)c2)[C@@H](CC(C)C)CN2CCCC2)cccc1 LAQRAWAMCKIRRY-BJMKKKEASA-N 0.000 description 1
- JFLGUQBBLMLIHL-VRJFXCOUSA-N CCC[C@@H](CN(C)C)N(Cc1cc(CN2OC(CO)[C@@H]([C@H](C)O)[C@H]2C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)ccc1)Cc(cccc1)c1Cl Chemical compound CCC[C@@H](CN(C)C)N(Cc1cc(CN2OC(CO)[C@@H]([C@H](C)O)[C@H]2C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)ccc1)Cc(cccc1)c1Cl JFLGUQBBLMLIHL-VRJFXCOUSA-N 0.000 description 1
- VPTSZLVPZCTAHZ-KZVJFYERSA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1N Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1N VPTSZLVPZCTAHZ-KZVJFYERSA-N 0.000 description 1
- MYSJFDFFBNKWCO-UWUCOLKPSA-N C[C@@H]([C@H]([C@H](CO)O)[C@@H](C(N[C@@H]1[C@@H](C)[C@H](C2)C(C)(C)[C@H]2C1)=C)NCc1cc(C=O)ccc1)O Chemical compound C[C@@H]([C@H]([C@H](CO)O)[C@@H](C(N[C@@H]1[C@@H](C)[C@H](C2)C(C)(C)[C@H]2C1)=C)NCc1cc(C=O)ccc1)O MYSJFDFFBNKWCO-UWUCOLKPSA-N 0.000 description 1
- WWFOCLNJQZYAJL-UNMPEWBMSA-N C[C@@H]([C@H]1[C@@H](C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cccc(CN(Cc3cccc(O)c3)[C@H](CN(C)C)c3ccccc3)c2)O[C@H]1CO)O Chemical compound C[C@@H]([C@H]1[C@@H](C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cccc(CN(Cc3cccc(O)c3)[C@H](CN(C)C)c3ccccc3)c2)O[C@H]1CO)O WWFOCLNJQZYAJL-UNMPEWBMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/600,332 US7842815B2 (en) | 2004-06-17 | 2006-11-15 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| US11/600,332 | 2006-11-15 | ||
| PCT/US2007/023941 WO2008060569A1 (en) | 2006-11-15 | 2007-11-14 | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20090082284A KR20090082284A (ko) | 2009-07-29 |
| KR101530721B1 true KR101530721B1 (ko) | 2015-06-22 |
Family
ID=39064388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097012239A Expired - Fee Related KR101530721B1 (ko) | 2006-11-15 | 2007-11-14 | Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는 화합물 및 방법 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7842815B2 (enExample) |
| EP (1) | EP2094673B1 (enExample) |
| JP (2) | JP2010510214A (enExample) |
| KR (1) | KR101530721B1 (enExample) |
| CN (1) | CN101583606B (enExample) |
| AU (1) | AU2007319848B2 (enExample) |
| BR (1) | BRPI0718606A2 (enExample) |
| CA (1) | CA2669596C (enExample) |
| EC (1) | ECSP099398A (enExample) |
| ES (1) | ES2537762T3 (enExample) |
| GT (1) | GT200900123A (enExample) |
| IL (1) | IL198597A (enExample) |
| MA (1) | MA31067B1 (enExample) |
| MX (1) | MX2009005184A (enExample) |
| MY (1) | MY156754A (enExample) |
| NO (1) | NO20092306L (enExample) |
| NZ (1) | NZ577243A (enExample) |
| RU (1) | RU2449996C2 (enExample) |
| TN (1) | TN2009000182A1 (enExample) |
| WO (1) | WO2008060569A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2677045C (en) | 2007-01-31 | 2016-10-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| KR101623985B1 (ko) | 2007-03-28 | 2016-05-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| CN101980718A (zh) | 2008-02-08 | 2011-02-23 | 爱勒让治疗公司 | 治疗性的拟肽大环化合物 |
| US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
| EP3367096B1 (en) | 2012-02-06 | 2019-11-27 | DiscoveRx Corporation | Detection of intracellular binding events by measuring protein abundance |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| CN103656642A (zh) * | 2012-08-31 | 2014-03-26 | 中国科学院上海生命科学研究院 | 预防和治疗结直肠癌的方法和试剂 |
| WO2014078014A2 (en) | 2012-11-14 | 2014-05-22 | Metabolix, Inc. | Production of salts of 4-hydroxybutyrate using biobased raw materials |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN106999541A (zh) | 2014-09-24 | 2017-08-01 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| MX2017011834A (es) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子 |
| NZ757763A (en) | 2016-03-28 | 2025-07-25 | Presage Biosciences Inc | Pharmaceutical combinations for the treatment of cancer |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| HUE060466T2 (hu) * | 2017-04-05 | 2023-03-28 | Harvard College | Makrociklusos vegyület és alkalmazása |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| US20230270816A1 (en) | 2020-07-06 | 2023-08-31 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006009869A1 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS55133364A (en) | 1979-04-03 | 1980-10-17 | Mitsubishi Petrochem Co Ltd | Preparation of isoxazolidine derivative |
| DE3643012A1 (de) | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| DE59010701D1 (de) | 1990-05-18 | 1997-05-22 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US5294617A (en) * | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| ES2134870T3 (es) * | 1993-05-01 | 1999-10-16 | Merck Patent Gmbh | Antagonistas del receptor de adhesion. |
| DK0730590T3 (da) | 1993-11-24 | 2001-03-19 | Du Pont Pharm Co | Isoxazolin og isozazol fibrinogenreceptorantagonister |
| JPH09505082A (ja) | 1994-03-09 | 1997-05-20 | ファイザー・インコーポレーテッド | Ｔｎｆ放出の阻害剤としてのイソオキサゾリン |
| US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| DE19539638A1 (de) | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
| US6221865B1 (en) * | 1995-11-06 | 2001-04-24 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| AU4064597A (en) | 1996-08-16 | 1998-03-06 | Du Pont Pharmaceuticals Company | Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof |
| WO1998016830A2 (en) | 1996-10-16 | 1998-04-23 | The President And Fellows Of Harvard College | Droplet assay system |
| CA2288330C (en) | 1997-05-07 | 2014-02-11 | University Of Pittsburgh | Benzoyl amino acid derivatives useful as inhibitors of protein isoprenyl tranferases |
| WO2001016115A1 (en) | 1999-09-01 | 2001-03-08 | Chemrx Advanced Technologies, Inc. | Process for synthesizing isoxazolidines |
| KR100399361B1 (ko) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| ES2349349T3 (es) | 2001-05-30 | 2010-12-30 | The Regents Of The University Of Michigan | Asociacion sinergica de (-)-gosipol con docetaxel o paclitaxel para el tratamiento de cancer. |
| FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
| US20060020004A1 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Isoxazolidine compounds for treatment of bacterial infections |
| TWI403320B (zh) * | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 |
-
2006
- 2006-11-15 US US11/600,332 patent/US7842815B2/en not_active Expired - Fee Related
-
2007
- 2007-11-14 RU RU2009121808/04A patent/RU2449996C2/ru not_active IP Right Cessation
- 2007-11-14 MY MYPI20091840A patent/MY156754A/en unknown
- 2007-11-14 AU AU2007319848A patent/AU2007319848B2/en not_active Ceased
- 2007-11-14 WO PCT/US2007/023941 patent/WO2008060569A1/en not_active Ceased
- 2007-11-14 BR BRPI0718606-1A patent/BRPI0718606A2/pt not_active IP Right Cessation
- 2007-11-14 KR KR1020097012239A patent/KR101530721B1/ko not_active Expired - Fee Related
- 2007-11-14 ES ES07840052.0T patent/ES2537762T3/es active Active
- 2007-11-14 CN CN200780049702.7A patent/CN101583606B/zh not_active Expired - Fee Related
- 2007-11-14 NZ NZ577243A patent/NZ577243A/en not_active IP Right Cessation
- 2007-11-14 CA CA2669596A patent/CA2669596C/en not_active Expired - Fee Related
- 2007-11-14 JP JP2009537198A patent/JP2010510214A/ja active Pending
- 2007-11-14 EP EP07840052.0A patent/EP2094673B1/en active Active
- 2007-11-14 MX MX2009005184A patent/MX2009005184A/es active IP Right Grant
-
2009
- 2009-05-06 IL IL198597A patent/IL198597A/en not_active IP Right Cessation
- 2009-05-08 TN TNP2009000182A patent/TN2009000182A1/fr unknown
- 2009-05-12 GT GT200900123A patent/GT200900123A/es unknown
- 2009-06-09 EC EC2009009398A patent/ECSP099398A/es unknown
- 2009-06-10 MA MA31972A patent/MA31067B1/fr unknown
- 2009-06-15 NO NO20092306A patent/NO20092306L/no not_active Application Discontinuation
-
2010
- 2010-11-30 US US12/956,969 patent/US8461191B2/en not_active Expired - Fee Related
-
2013
- 2013-11-07 JP JP2013230960A patent/JP2014055156A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006009869A1 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2094673A1 (en) | 2009-09-02 |
| RU2009121808A (ru) | 2010-12-20 |
| BRPI0718606A2 (pt) | 2013-12-17 |
| ECSP099398A (es) | 2009-07-31 |
| US8461191B2 (en) | 2013-06-11 |
| WO2008060569A1 (en) | 2008-05-22 |
| TN2009000182A1 (en) | 2010-10-18 |
| GT200900123A (es) | 2011-09-02 |
| AU2007319848B2 (en) | 2012-05-03 |
| MX2009005184A (es) | 2009-10-12 |
| NO20092306L (no) | 2009-08-17 |
| MY156754A (en) | 2016-03-31 |
| CA2669596A1 (en) | 2008-05-22 |
| ES2537762T3 (es) | 2015-06-11 |
| US7842815B2 (en) | 2010-11-30 |
| US20070161690A1 (en) | 2007-07-12 |
| CA2669596C (en) | 2014-09-30 |
| NZ577243A (en) | 2011-12-22 |
| HK1130057A1 (en) | 2009-12-18 |
| JP2014055156A (ja) | 2014-03-27 |
| JP2010510214A (ja) | 2010-04-02 |
| US20080306127A9 (en) | 2008-12-11 |
| US20110160259A1 (en) | 2011-06-30 |
| MA31067B1 (fr) | 2010-01-04 |
| RU2449996C2 (ru) | 2012-05-10 |
| CN101583606A (zh) | 2009-11-18 |
| IL198597A (en) | 2014-03-31 |
| AU2007319848A1 (en) | 2008-05-22 |
| EP2094673B1 (en) | 2015-04-08 |
| IL198597A0 (en) | 2010-02-17 |
| KR20090082284A (ko) | 2009-07-29 |
| CN101583606B (zh) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101530721B1 (ko) | Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는 화합물 및 방법 | |
| KR101195351B1 (ko) | Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는화합물 및 방법 | |
| KR101454936B1 (ko) | Ｂｃｌ 단백질과 결합 파트너의 상호작용을 억제하기 위한 화합물 및 방법 | |
| WO2017162108A1 (zh) | 一种柱芳烃类复合物、其制备方法、药物组合物和用途 | |
| KR20140107574A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| KR20140107575A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| KR20140107578A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| CN106831614A (zh) | 取代的苯并二氮杂环类化合物及其制备方法和用途 | |
| CN112654626A (zh) | 化合物及其用途 | |
| JP5341521B2 (ja) | タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法 | |
| HK1130057B (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20180617 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20180617 |